Clinical and laboratory safety of one year's use of a combination calcium + vitamin D tablet in ambulatory elderly women with vitamin D insufficiency: results of a multicenter, randomized, double-blind, placebo-controlled study.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.

Who Took Part

By PubMed's age tags, the people studied were older adults, women only.

Safety was monitored based on adverse events recorded during the treatment period and on the results of laboratory tests, including measurement of creatinine and uric acid levels.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and multicenter.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.

Some participants received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

Running at several centres spread the Vitamin D, K2, Magnesium and Zinc study over different clinics and patient groups.

What Was Measured

Topics PubMed links to this paper include Bone Density Conservation Agents, Calcium, Calcium Carbonate, Cholecalciferol, Creatine, Dietary Supplements and Drug Combinations.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc.

Its findings take up roughly 9 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2005 (Clinical therapeutics), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.